%0 Journal Article %J Am J Hum Genet %D 2021 %T Association of structural variation with cardiometabolic traits in Finns. %A Chen, Lei %A Abel, Haley J %A Das, Indraniel %A Larson, David E %A Ganel, Liron %A Kanchi, Krishna L %A Regier, Allison A %A Young, Erica P %A Kang, Chul Joo %A Scott, Alexandra J %A Chiang, Colby %A Wang, Xinxin %A Lu, Shuangjia %A Christ, Ryan %A Service, Susan K %A Chiang, Charleston W K %A Havulinna, Aki S %A Kuusisto, Johanna %A Boehnke, Michael %A Laakso, Markku %A Palotie, Aarno %A Ripatti, Samuli %A Freimer, Nelson B %A Locke, Adam E %A Stitziel, Nathan O %A Hall, Ira M %K Alleles %K Cardiovascular Diseases %K Cholesterol %K DNA Copy Number Variations %K Female %K Finland %K Genome, Human %K Genomic Structural Variation %K Genotype %K High-Throughput Nucleotide Sequencing %K Humans %K Male %K Mitochondrial Proteins %K Promoter Regions, Genetic %K Pyruvate Dehydrogenase (Lipoamide)-Phosphatase %K Pyruvic Acid %K Serum Albumin, Human %X

The contribution of genome structural variation (SV) to quantitative traits associated with cardiometabolic diseases remains largely unknown. Here, we present the results of a study examining genetic association between SVs and cardiometabolic traits in the Finnish population. We used sensitive methods to identify and genotype 129,166 high-confidence SVs from deep whole-genome sequencing (WGS) data of 4,848 individuals. We tested the 64,572 common and low-frequency SVs for association with 116 quantitative traits and tested candidate associations using exome sequencing and array genotype data from an additional 15,205 individuals. We discovered 31 genome-wide significant associations at 15 loci, including 2 loci at which SVs have strong phenotypic effects: (1) a deletion of the ALB promoter that is greatly enriched in the Finnish population and causes decreased serum albumin level in carriers (p = 1.47 × 10) and is also associated with increased levels of total cholesterol (p = 1.22 × 10) and 14 additional cholesterol-related traits, and (2) a multi-allelic copy number variant (CNV) at PDPR that is strongly associated with pyruvate (p = 4.81 × 10) and alanine (p = 6.14 × 10) levels and resides within a structurally complex genomic region that has accumulated many rearrangements over evolutionary time. We also confirmed six previously reported associations, including five led by stronger signals in single nucleotide variants (SNVs) and one linking recurrent HP gene deletion and cholesterol levels (p = 6.24 × 10), which was also found to be strongly associated with increased glycoprotein level (p = 3.53 × 10). Our study confirms that integrating SVs in trait-mapping studies will expand our knowledge of genetic factors underlying disease risk.

%B Am J Hum Genet %V 108 %P 583-596 %8 2021 04 01 %G eng %N 4 %1 https://www.ncbi.nlm.nih.gov/pubmed/33798444?dopt=Abstract %R 10.1016/j.ajhg.2021.03.008 %0 Journal Article %J Trends Cardiovasc Med %D 2017 %T Genetic association studies in cardiovascular diseases: Do we have enough power? %A Auer, Paul L %A Stitziel, Nathan O %K Cardiovascular Diseases %K Data Accuracy %K Data Interpretation, Statistical %K Genetic Association Studies %K Genetic Markers %K Genetic Predisposition to Disease %K Genetic Variation %K Humans %K Phenotype %K Reproducibility of Results %K Research Design %K Risk Assessment %K Risk Factors %X

Genetic association studies have a long history of delivering insightful results for cardiovascular disease (CVD) research. Beginning with early candidate gene studies, to genome-wide association studies, and now on to newer whole-genome sequencing studies, research in human genetics has enriched our understanding of the pathobiology of CVD. As these studies continue to expand, the issue of statistical power plays an important role in study design as well as the interpretation of results. We provide an overview of the component parts that determine statistical power and preview the future of CVD genetic association studies through this lens.

%B Trends Cardiovasc Med %V 27 %P 397-404 %8 2017 08 %G eng %N 6 %1 https://www.ncbi.nlm.nih.gov/pubmed/28456354?dopt=Abstract %R 10.1016/j.tcm.2017.03.005 %0 Journal Article %J Curr Opin Lipidol %D 2017 %T Human genetic insights into lipoproteins and risk of cardiometabolic disease. %A Stitziel, Nathan O %K Cardiovascular Diseases %K Genetic Predisposition to Disease %K Humans %K Lipoproteins %K Risk %X

PURPOSE OF REVIEW: Human genetic studies have been successfully used to identify genes and pathways relevant to human biology. Using genetic instruments composed of loci associated with human lipid traits, recent studies have begun to clarify the causal role of major lipid fractions in risk of cardiometabolic disease.

RECENT FINDINGS: The causal relationship between LDL cholesterol and coronary disease has been firmly established. Of the remaining two major fractions, recent studies have found that HDL cholesterol is not likely to be a causal particle in atherogenesis, and have instead shifted the causal focus to triglyceride-rich lipoproteins. Subsequent results are refining this view to suggest that triglycerides themselves might not be causal, but instead may be a surrogate for the causal cholesterol content within this fraction. Other studies have used a similar approach to address the association between lipid fractions and risk of type 2 diabetes. Beyond genetic variation in the target of statin medications, reduced LDL cholesterol associated with multiple genes encoding current or prospective drug targets associated with increased diabetic risk. In addition, genetically lower HDL cholesterol and genetically lower triglycerides both appear to increase risk of type 2 diabetes.

SUMMARY: Results of these and future human genetic studies are positioned to provide substantive insights into the causal relationship between lipids and human disease, and should highlight mechanisms with important implications for our understanding of human biology and future lipid-altering therapeutic development.

%B Curr Opin Lipidol %V 28 %P 113-119 %8 2017 Apr %G eng %N 2 %1 https://www.ncbi.nlm.nih.gov/pubmed/28059951?dopt=Abstract %R 10.1097/MOL.0000000000000389